Study of IASO-782 for autoimmune blood disorders
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests a new drug called IASO-782 for people with immune thrombocytopenia (ITP) or warm autoimmune hemolytic anemia (wAIHA) who haven't gotten better with standard treatments. The goal is to see if the drug can help control the immune system and improve blood counts.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have immune thrombocytopenia (ITP) or warm autoimmune hemolytic anemia (wAIHA).
- At least one prior treatment for your condition has failed or stopped working.
- You are on a stable dose of immunosuppressant drugs for at least 4 weeks.
- You have no history of cancer in the last 5 years, active infections, or serious heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called IASO208 for people with certain types of B-cell lymphoma that have come back or not responded to standard treatments. It aims to see if the drug can help shrink tumors and control the cancer.
This study tests a new medication called SHR-2173 for people with immune thrombocytopenia (ITP) whose platelet count is low and who have already tried steroids without success. The goal is to see if this drug can help raise platelet counts and reduce bleeding risk.
This trial tests a new medicine called IASO-782 for people with systemic lupus erythematosus (SLE). It aims to see if the drug can help control lupus symptoms when added to standard treatments.
This trial tests a new type of cell therapy (IASO206) for patients whose autoimmune hemolytic anemia (a condition where the body attacks its own red blood cells) has not responded to standard treatments. The therapy is designed to target and control the immune cells causing the problem.
This study tests a new drug, tafasitamab, for people with immune thrombocytopenia (ITP) or warm autoimmune hemolytic anemia (wAIHA) that has not been controlled well by other treatments. The goal is to see if it is safe and can help manage these blood cell disorders.
This trial tests a new drug called STSA-1301 for people with immune thrombocytopenia (ITP), a condition where the immune system attacks platelets. The study has two parts: one for healthy volunteers to check safety, and one for ITP patients to see if the drug can raise platelet counts and reduce bleeding risk.
Hear when a new Autoimmune Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.